Summit Trail Advisors LLC Buys 192 Shares of Edwards Lifesciences Co. (NYSE:EW)

Summit Trail Advisors LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,522 shares of the medical research company’s stock after acquiring an additional 192 shares during the period. Summit Trail Advisors LLC’s holdings in Edwards Lifesciences were worth $1,031,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock worth $3,577,163,000 after buying an additional 325,808 shares in the last quarter. Wellington Management Group LLP raised its stake in Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after buying an additional 1,390,427 shares in the last quarter. Northern Trust Corp raised its stake in Edwards Lifesciences by 3.9% in the third quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock worth $440,446,000 after buying an additional 241,347 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its stake in Edwards Lifesciences by 16.8% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company’s stock worth $312,625,000 after buying an additional 590,000 shares in the last quarter. Finally, Ownership Capital B.V. raised its stake in Edwards Lifesciences by 21.3% in the fourth quarter. Ownership Capital B.V. now owns 3,489,915 shares of the medical research company’s stock worth $266,106,000 after buying an additional 613,817 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of several analyst reports. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Mizuho boosted their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Finally, Royal Bank of Canada boosted their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. One analyst has rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $92.71.

Edwards Lifesciences Trading Down 0.2 %

Shares of NYSE:EW traded down $0.16 during mid-day trading on Monday, reaching $85.09. 2,438,926 shares of the company were exchanged, compared to its average volume of 3,757,333. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The firm has a market cap of $51.28 billion, a price-to-earnings ratio of 36.68, a P/E/G ratio of 3.59 and a beta of 1.10. The firm’s 50-day simple moving average is $90.08 and its 200 day simple moving average is $79.46. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total transaction of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares in the company, valued at $3,390,542.49. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Catherine M. Szyman sold 27,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares in the company, valued at approximately $2,980,774.68. The disclosure for this sale can be found here. Insiders sold a total of 237,749 shares of company stock valued at $20,920,934 over the last ninety days. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.